Literature DB >> 29061027

[Lung cancer incidence and mortality in China in 2013].

W Q Chen1, T T Zuo1, R S Zheng1, H M Zeng1, S W Zhang1, J He2.   

Abstract

Objective: Lung cancer incidence and mortality were estimated by sorting and analyzing the national cancer registration data in 2013.
Methods: Lung cancer data of 2013 were retrieved from the database of 255 qualified cancer registries. Lung cancer incidence and mortality rates in cancer registration areas in 2013 were estimated by areas (urban/rural), gender and age groups, new lung cancer cases and deaths were estimated using age-specific rates by areas and gender using the corresponding population in 2013. Lung cancer incidence and mortality rates in China in 2013 were calculated based on the estimated new cancer cases and deaths and the corresponding population. The Chinese population in 2000 and Segi's world population were used to calculate age-standardized rates.
Results: It was estimated that there were about 732.8 thousand new lung cancer cases and 580.7 thousand deaths occurred in China in 2013. The crude incidence rate was 53.86/10(5)(males 70.10/10(5,) females 36.78/10(5)), while age-standardized incidence rate by Chinese standard populations (ASIRC) and by world standard populations (ASIRW) were 36.19/10(5) and 36.09/10(5) with the cumulative incidence rate (0-74 years old) of 4.42%.The crude mortality rate was 43.41/10(5)(males 57.64/10(5,) females 28.45/10(5)), and age-standardized mortality rate by Chinese standard populations (ASMRC) and by world standard populations (ASMRW) were 28.64/10(5) and 28.41/10(5) with the cumulative incidence rate (0-74 years old) of 3.34%.Both incidence and mortality rates were higher in males than in females. Crude incidence and mortality rates were slightly higher in urban areas than in rural areas, but after age standardized, the results were opposite. Conclusions: Lung cancer is the common cancer, which both incidence and mortality rates are ranking first in China, and the burden of the disease is heavy. Comprehensive measures towards risk factors control, cancer early diagnosis and treatment should be strengthened continuously.

Entities:  

Keywords:  Cancer registration; China; Incidence; Lung neoplasms; Mortality

Mesh:

Year:  2017        PMID: 29061027     DOI: 10.3760/cma.j.issn.0253-3766.2017.10.015

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  11 in total

1.  TFAP2A Induced KRT16 as an Oncogene in Lung Adenocarcinoma via EMT.

Authors:  Liu Yuanhua; Qian Pudong; Zhu Wei; Wu Yuan; Liu Delin; Zhang Yan; Liang Geyu; Shen Bo
Journal:  Int J Biol Sci       Date:  2019-06-02       Impact factor: 6.580

2.  Trend analysis of lung cancer mortality and years of life lost (YLL) rate from 1999 to 2016 in Tianjin, China: Does the lung cancer burden in rural areas exceed that of urban areas?

Authors:  Wenlong Zheng; Hui Zhang; Chengfeng Shen; Shuang Zhang; Dezheng Wang; Wei Li; Guohong Jiang
Journal:  Thorac Cancer       Date:  2020-03-03       Impact factor: 3.500

3.  miR-130a-Mediated KLF3 Can Inhibit the Growth of Lung Cancer Cells.

Authors:  Ming-Chao Wei; Yu-Min Wang; Da-Wei Wang
Journal:  Cancer Manag Res       Date:  2021-04-06       Impact factor: 3.989

4.  Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China.

Authors:  Jin Shi; Daojuan Li; Di Liang; Yutong He
Journal:  Sci Rep       Date:  2021-03-25       Impact factor: 4.379

5.  Meta-Analysis of Aidi Injection and First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Treating Advanced Non-Small Cell Lung Cancer.

Authors:  Na Xiao; Hailang He; Jing Wang; Li Zhang; Brandon Chow; Fanchao Feng; Yong Xu; Jingyi Huang; Xianmei Zhou; Rui Dong
Journal:  J Evid Based Integr Med       Date:  2021 Jan-Dec

6.  Identification of Key Genes and Pathways in Gefitinib-Resistant Lung Adenocarcinoma using Bioinformatics Analysis.

Authors:  Kailin Mao; Fang Lin; Yingai Zhang; Hailong Zhou
Journal:  Evol Bioinform Online       Date:  2021-06-11       Impact factor: 1.625

7.  Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone.

Authors:  Yujia Wang; Guoyu Wu; Ru Li; Yingzhe Luo; Xingmei Huang; Lifang He; Huihui Zhong; Shaoquan Xiong
Journal:  Front Public Health       Date:  2021-06-18

8.  Independent prognostic value of HIF-1α expression in radiofrequency ablation of lung cancer.

Authors:  Jun Wan; Xiean Ling; Zhanpeng Rao; Bin Peng; Guanggui Ding
Journal:  Oncol Lett       Date:  2019-11-21       Impact factor: 2.967

9.  Three-dimensional printing technology for localised thoracoscopic segmental resection for lung cancer: a quasi-randomised clinical trial.

Authors:  Yangming Chen; Jiguang Zhang; Qianshun Chen; Tian Li; Kai Chen; Qinghua Yu; Xing Lin
Journal:  World J Surg Oncol       Date:  2020-08-24       Impact factor: 2.754

10.  Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma.

Authors:  Yanjie Zhao; Feng Shi; Quan Zhou; Yuchen Li; Jiangping Wu; Ruibin Wang; Qingkun Song
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.